We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Bimatoprost Versus Travoprost at Cairo University

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01092273
Recruitment Status : Completed
First Posted : March 24, 2010
Last Update Posted : March 24, 2010
Information provided by:
Cairo University

Brief Summary:

Bimatoprost has been shown to provide effective IOP lowering in patients of all races. Conversely, travoprost has been shown to be more effective in black patients than in Caucasians in some studies. However, Noecker et al 2004 compared bimatoprost with travoprost in African-Americans with glaucoma or OHT, and found that bimatoprost was more likely than travoprost to achieve target pressure at 3 months.

These racial differences in efficacy of these medications warrant further investigations. The investigators study aim to compare the IOP-lowering efficacies of bimatoprost and travoprost in an Egyptian population with primary open-angle glaucoma (OAG) or ocular hypertension (OHT).

Condition or disease
Glaucoma Ocular Hypertension

Study Type : Observational
Time Perspective: Prospective
Official Title: Bimatoprost Versus Travoprost in an Egyptian Population: A Hospital-Based Prospective Randomized Study.

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Glaucoma
U.S. FDA Resources

Bimatoprost versus Travoprost

Primary Outcome Measures :
  1. Percentage of intraocular pressure lowering of bimatoprost versus travoprost.

Secondary Outcome Measures :
  1. Rate of development of complications.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 72 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
Hospital Based Study at Cairo University and Al Nour Eye Hospital

Inclusion Criteria:

  • Glaucoma and Ocular Hypertension

Exclusion Criteria:

  • Any ocular disease or medication that may raise the intraocular pressure.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01092273

Cairo University
Cairo, Egypt, 11431
Sponsors and Collaborators
Cairo University

Additional Information:
ClinicalTrials.gov Identifier: NCT01092273     History of Changes
Other Study ID Numbers: Prostaglandins-Cairo-1A
First Posted: March 24, 2010    Key Record Dates
Last Update Posted: March 24, 2010
Last Verified: January 2008

Keywords provided by Cairo University:
Glaucoma and Ocular Hypertension

Additional relevant MeSH terms:
Ocular Hypertension
Vascular Diseases
Cardiovascular Diseases
Eye Diseases
Antihypertensive Agents